PL3645034T3 - 21-dniowy schemat dawkowania białek fuzyjnych zawierających czynnik ix i ludzką albuminę do profilaktycznego leczenia hemofilii i sposoby - Google Patents

21-dniowy schemat dawkowania białek fuzyjnych zawierających czynnik ix i ludzką albuminę do profilaktycznego leczenia hemofilii i sposoby

Info

Publication number
PL3645034T3
PL3645034T3 PL18736860.0T PL18736860T PL3645034T3 PL 3645034 T3 PL3645034 T3 PL 3645034T3 PL 18736860 T PL18736860 T PL 18736860T PL 3645034 T3 PL3645034 T3 PL 3645034T3
Authority
PL
Poland
Prior art keywords
hemophilia
factor
methods
fusion proteins
dosing regimen
Prior art date
Application number
PL18736860.0T
Other languages
English (en)
Polish (pl)
Inventor
Yanyan LI
Debra BENSEN-KENNEDY
Iris JACOBS
Christine VOIGT
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of PL3645034T3 publication Critical patent/PL3645034T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL18736860.0T 2017-06-29 2018-06-29 21-dniowy schemat dawkowania białek fuzyjnych zawierających czynnik ix i ludzką albuminę do profilaktycznego leczenia hemofilii i sposoby PL3645034T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762526377P 2017-06-29 2017-06-29
PCT/EP2018/067523 WO2019002532A1 (en) 2017-06-29 2018-06-29 21-DAY FUSION PROTEIN DRAFTING COMPRISING IX FACTOR AND HUMAN ALBUMIN FOR THE PROPHYLACTIC TREATMENT OF HEMOPHILIA AND ASSOCIATED METHODS

Publications (1)

Publication Number Publication Date
PL3645034T3 true PL3645034T3 (pl) 2024-09-02

Family

ID=62815032

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18736860.0T PL3645034T3 (pl) 2017-06-29 2018-06-29 21-dniowy schemat dawkowania białek fuzyjnych zawierających czynnik ix i ludzką albuminę do profilaktycznego leczenia hemofilii i sposoby

Country Status (15)

Country Link
US (1) US20200115436A1 (enExample)
EP (1) EP3645034B1 (enExample)
JP (1) JP2020525498A (enExample)
KR (1) KR102597725B1 (enExample)
CN (1) CN110799209A (enExample)
AU (1) AU2018294517B2 (enExample)
CA (1) CA3068360A1 (enExample)
DK (1) DK3645034T5 (enExample)
ES (1) ES2963665T3 (enExample)
IL (1) IL271160B2 (enExample)
MX (1) MX2019014651A (enExample)
PL (1) PL3645034T3 (enExample)
RU (1) RU2020103424A (enExample)
SG (1) SG10202111032PA (enExample)
WO (1) WO2019002532A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
AU2011274414B2 (en) * 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
HK1213521A1 (zh) * 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
KR20160093735A (ko) * 2013-12-23 2016-08-08 시에스엘 리미티드 혈우병의 예방학적 치료를 위한 인자 ix를 포함하는 융합 단백질 및 이의 방법
SG11201608006QA (en) * 2014-04-11 2016-10-28 Csl Ltd Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor

Also Published As

Publication number Publication date
AU2018294517A1 (en) 2020-01-30
DK3645034T5 (da) 2024-08-26
WO2019002532A1 (en) 2019-01-03
MX2019014651A (es) 2020-02-07
KR20200019749A (ko) 2020-02-24
CN110799209A (zh) 2020-02-14
IL271160B2 (en) 2025-05-01
IL271160A (en) 2020-01-30
US20200115436A1 (en) 2020-04-16
RU2020103424A (ru) 2021-07-29
DK3645034T3 (da) 2023-11-20
AU2018294517B2 (en) 2024-09-26
RU2020103424A3 (enExample) 2021-11-12
JP2020525498A (ja) 2020-08-27
EP3645034B1 (en) 2023-08-30
ES2963665T3 (es) 2024-04-01
IL271160B1 (en) 2025-01-01
CA3068360A1 (en) 2019-01-03
KR102597725B1 (ko) 2023-11-06
SG10202111032PA (en) 2021-11-29
EP3645034A1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
IL257231A (en) Factor ix fusion proteins and methods for their preparation and use
IL273918A (en) Trispecific proteins and methods of use
ZA202003695B (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
IL262831A (en) Medical implants and methods for their preparation
SG10201912680RA (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3464608A4 (en) THERAPEUTIC RECOMBINANT KLOTHO PROTEINS, COMPOSITIONS AND METHODS THEREFOR
PT3310805T (pt) Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
EP3490538A4 (en) PARTICLES FOR THE DELIVERY OF PROTEINS AND PEPTIDES
IL256515A (en) Therapeutic peptides and methods of use thereof
EP3518971A4 (en) Antibody and protein therapeutic formulations and uses thereof
CL2018001724A1 (es) Terapia combinada de inhibidores de proteinas extra-terminales y bromodominio
EP3294286A4 (en) Docetaxel and human serum albumin complexes
SI3532059T1 (sl) Kombinacijska terapija z bromodomeno in ekstra terminalnim inhibitorskim proteinom
PT3387019T (pt) Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
IL245997A0 (en) Fusion proteins containing factor ix for prophylactic treatment of hemophilia and methods of treatment
IL262508A (en) Methods and compositions for the treatment of degenerate bone
IL261740A (en) Compositions and methods for treatment of type vii collagen deficiencies
EP3305800C0 (en) METHOD FOR PREPARING PLASMA-DERIVED HUMAN IMMUNOGLOBULIN AGENT AGAINST HEPATITIS B
IL258238B (en) Hiv antibody compositions and methods of use
SG10202111032PA (en) 21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof
HUP1700057A2 (en) Capsule configuration for slides and adventure field in amusement complex system
EP3474826A4 (en) PHARMACEUTICAL PREPARATION FOR THE ADMINISTRATION OF PEPTIDES AND PROTEINS
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu